Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF | Spanish ecancer 12 835 / https://doi.org/10.3332/ecancer.2018.835

Research

Phase I/II study on kilovoltage surface brachytherapy in conjunctival cancer: preliminary results

Introduction: In ocular conjunctival carcinoma after surgery, adjuvant treatment has a role and kilovoltage surface brachytherapy opens a new door for the range of therapeutic options.

Materials and methods: Between October 2014 and June 2017, at the National Institute of Neoplastic Diseases (INEN) from Peru, 39 patients with squamous cell carcinoma of ocular conjunctiva, T1–T3, resected, were selected to receive adjuvant treatment. The portable accelerator of 50-kV INTRABEAM (Carl Zeiss Meditec) was used, after local anaesthesia and blocking of ocular muscles movement. The doses used were 18 Gy for patients with free margins and 22 Gy for positive edges, according to calculation of equivalent dose of 2Gy per fraction of 46 and 66 Gy, respectively, assuming a tumoural α/β ratio of 8 Gy. The prescription was done to 2 mm depth.

Results: The median age was 69 years, distributed evenly between both genders, with a median follow-up of 12 months. The surgical margins were 59% free and 41% committed, with no difference between the institutions where the surgery was performed (P = 0.069). The median tumour size was 7 mm with 2 mm of invasion, 61.5% was T2 and 35.9% T1. The mean time between surgery and irradiation was 1.5 months, 23.1% of patients developed grade I toxicity of spontaneous resolution, without evidence of greater degree in any case. The dose had no statistical relationship with toxicity (P = 0.533). One-year disease-free survival was 96.7%.

Conclusions: Kilovoltage surface brachytherapy is an applicable and reproducible tool in the treatment of squamous cell carcinoma of ocular conjunctiva. The administered doses are well tolerated by patients with low levels of acute toxicity. Longer follow-up is needed to establish disease control rates and late toxicities.

Keywords: surface brachytherapy, kilovoltage, conjunctival carcinoma

Loading Article Metrics ... Please wait

Related articles

Review: Conservative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women

Abstract | Full Article | PDF Published: 17 Jan 2019 / https://doi.org/10.3332/ecancer.2019.892

Research: Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer

Abstract | Full Article | PDF Published: 15 Jan 2019 / https://doi.org/10.3332/ecancer.2019.891

Research: Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status

Abstract | Full Article | PDF Published: 08 Jan 2019 / https://doi.org/10.3332/ecancer.2019.890

Research: The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B

Abstract | Full Article | PDF Published: 21 Dec 2018 / https://doi.org/10.3332/ecancer.2018.889

Review: Spontaneous testicular tumor regression: case report and historical review

Abstract | Full Article | PDF | Spanish Published: 18 Dec 2018 / https://doi.org/10.3332/ecancer.2018.888



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation